

June 26th, 2015
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS

TOKYO, Japan, June 26th, 2015 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") announced the completion of its Japan Phase I clinical trial for oral rigosertib (SyB C-1101, oral formulation) in transfusion-dependent lower risk myelodysplastic syndrome (MDS) patients.

Preparations are underway for further development of oral rigosertib in the target indications of higher risk MDS in combination with azacitidine, and transfusion-dependent lower risk MDS. The Company's participation in a global Phase III trial to be conducted by Onconova Therapeutics is under consideration.

Regarding the IV formulation of rigosertib, patient enrollment of the Japan Phase I trial in refractory or relapsed higher risk MDS patients was completed in January, 2015, with positive results as the Company works toward trial completion.

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower and higher risk MDS.

Completion of the Phase I trial for oral rigosertib will have no impact on the Company's financial forecast for FY2015.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125

[Please read the following for more information on Onconova and Symbio]**About Onconova Therapeutics, Inc.**

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and autoimmune disease.